2303 Dawn
- 1967
- +9+0.46%
Dawn News
Tesla partners with Baidu to overcome hurdles in China
[Autonomous driving car] It is reported that US Tesla is a partnership with Baidu regarding maps and navigation functions, and the direction of overcoming major hurdles for introducing advanced driving support functions in China and related sources. It is reported that it will be possible to develop autonomous driving services based on lane-level navigation and mapping provided by Baidu. ＜7203＞Toyota Motor ＜6902＞Denso ＜3663＞Art Spark ＜3906＞ALBER
Dawn --- dividend policy changes and dividend forecast revisions (dividend increase)
Dawn ＜2303＞ announced on the 8th that it will change its dividend policy and introduce progressive dividends. Note that progressive dividends will be applied from the 2024/5 fiscal year, and dividend forecasts will be revised in accordance with this dividend policy. Progressive dividends are dividend policies that maintain or increase dividends without reducing dividends in principle. The company plans to increase dividends for 9 consecutive terms in the 2024/5 fiscal year. In order to make it clear that these results will continue, it has been decided to introduce progressive dividends this time. Regarding revisions to dividend forecasts
Dawn --- 3Q profit increase, year-end dividend increase announced
Dawn ＜2303＞ announced financial results for the 3rd quarter (23/6/24 to 2/24) of the fiscal year ending 2024/5 on the 8th. Net sales decreased 2.0% from the same period last year to 964 million yen, operating profit increased 1.4% to 330 million yen, ordinary profit increased 3.7% to 343 million yen, and quarterly net profit increased 5.00% to 243 million yen. While promoting “deepening the Gov-tech market,” which is the top priority policy of the 2022 medium-term management plan, the company aims to achieve stretch targets, “Social Affairs Division”
Fuji's 24/2 operating profit increased 33.5% to 15.1 billion yen, 25/2 forecast 2.6% increase 15.5 billion yen
As for the financial results for the fiscal year ending 2024/2 announced by Fuji ＜8278＞, operating revenue was 801,022 billion yen, up 2% from the previous fiscal year, and operating profit was 15.110 billion yen, up 33.5% from the same period. The earnings forecast was revised upward on the 3rd, and it landed in line with this. In addition to cost reduction effects etc. by creating integrated synergy effects, we worked to improve productivity by utilizing process centers and promoting digitalization. The financial results for the fiscal year ending 2025/2 were 810 billion yen, up 1.1% from the previous fiscal year, and sales
Welcia HD, Create SD, MS Consulting, Nakamoto Pax (8th)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------4/8 (Mon) ＜2303＞Dawn ＜2408＞KG Information＜3141＞Welcia HD ＜3148＞Create SD ＜3236＞Propriest ＜3280＞East Trust ＜4714＞Riso Education ＜4992＞Hokkokka＜655
Q1 2023 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Increased by Analyst
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) – Equities research analysts at Capital One Financial lifted their Q1 2023 EPS estimates for Day One Biopharmaceuticals in a report releas
Jeremy Bender Sells 12,500 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CEO Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, March 7th. The stock was sold at an
P&G Professional Celebrates National Dishwasher Appreciation Day by Partnering With Celebrity Chef Jet Tila to Introduce the New Dawn Professional Heavy Duty Manual Pot and Pan Detergent
Formulated for the Toughest Grease, the New Dawn Professional Heavy Duty Will Help Make Dishwashing Easier and Give Restaurants a Clean Their Customers Can Trust The service industry can be busy and stressful, and in
HC Wainwright Reiterates "Buy" Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Reiterated by Needham & Company LLC
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating)'s stock had its "buy" rating reaffirmed by equities researchers at Needham & Company LLC in a report released on Tuesday, Benzinga reports. They p
By Dawn's Early Light: New Book WITH THE SUN'S RISING Explores The Promise Of A New Day
Charleston, SC, March 08, 2023 (GLOBE NEWSWIRE) -- They say the only constant in life is change. Life is marked by changes, some small and some profound. And with change, comes new possibilities. For author John W.
Wayfinder Family Services Appoints Dawn Vo-Jutabha, Ph.D. as Chief Operating Officer
LOS ANGELES, March 8, 2023 /PRNewswire/ -- Dawn Vo-Jutabha, Ph.D. has joined Wayfinder Family Services as executive vice president and chief operating officer. In this role she will also serve as Wayfinder's chief
Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Smart Refrigerators Global Market Report 2023: Dawn of the IoT at Home Spurs Further Growth in the Sector - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Smart Refrigerators Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global smart refrigerators market will grow from $4.89 bill
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up to $18.74
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) shares gapped up before the market opened on Monday . The stock had previously closed at $18.74, but opened at $19.51. Day One Biopharmaceut
JonesTrading Remains a Buy on Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 6.6% in February
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 5,690,000 shares, a
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Tenax Therapeutics (TENX) and Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals (DAWN) Gets a Hold From Oppenheimer
Dawn Health Expands Mental Health Therapist Coverage for Millions of Floridians
SAN FRANCISCO--(BUSINESS WIRE)--Today, Dawn Health, the leading national provider of Sleep Therapy, announced it has expanded coverage to include millions of Floridians suffering from Insomnia and rel
Analysis
Price Target
No Data
